Targeting Endothelial Dysfunction in Eight Extreme-Critically Ill Patients with COVID-19 Using the Anti-Adrenomedullin Antibody Adrecizumab (HAM8101)
使用抗肾上腺髓质素抗体 Adrecizumab (HAM8101) 治疗 8 名 COVID-19 重症患者的内皮功能障碍
期刊:Biomolecules
影响因子:4.8
doi:10.3390/biom10081171
Mahir Karakas, Dominik Jarczak, Martin Becker, Kevin Roedl, Marylyn M Addo, Frauke Hein, Andreas Bergmann, Jens Zimmermann, Tim-Philipp Simon, Gernot Marx, Marc Lütgehetmann, Axel Nierhaus, Stefan Kluge
